Dermira, Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 500 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $27.58, for a total value of $13,790.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Thomas G. Wiggans also recently made the following trade(s):
- On Monday, July 3rd, Thomas G. Wiggans sold 5,000 shares of Dermira stock. The shares were sold at an average price of $29.06, for a total value of $145,300.00.
- On Friday, June 2nd, Thomas G. Wiggans sold 5,000 shares of Dermira stock. The shares were sold at an average price of $27.52, for a total value of $137,600.00.
Dermira, Inc. (NASDAQ DERM) traded up 3.15% during mid-day trading on Friday, hitting $23.25. The stock had a trading volume of 382,274 shares. Dermira, Inc. has a 52 week low of $21.35 and a 52 week high of $38.75. The stock’s 50-day moving average is $28.06 and its 200 day moving average is $30.67. The company’s market capitalization is $966.99 million.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.04. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The business had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million. Equities analysts forecast that Dermira, Inc. will post ($4.17) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://rinconhillneighbors.org/2017/08/13/dermira-inc-nasdaqderm-ceo-sells-13790-00-in-stock-updated.html.
Several large investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Dermira by 4,816.7% in the first quarter. BlackRock Inc. now owns 3,392,848 shares of the biopharmaceutical company’s stock worth $115,729,000 after buying an additional 3,323,841 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Dermira during the first quarter worth about $20,296,000. Marshall Wace North America L.P. purchased a new stake in shares of Dermira during the first quarter worth about $20,296,000. Jana Partners LLC boosted its stake in shares of Dermira by 171.0% in the first quarter. Jana Partners LLC now owns 655,252 shares of the biopharmaceutical company’s stock worth $22,351,000 after buying an additional 413,442 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Dermira by 16.7% in the second quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock worth $76,725,000 after buying an additional 377,554 shares in the last quarter. Institutional investors own 84.57% of the company’s stock.
Several research analysts recently weighed in on the company. BidaskClub lowered Dermira from a “sell” rating to a “strong sell” rating in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Tuesday, July 18th. Cantor Fitzgerald assumed coverage on Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock. Evercore ISI assumed coverage on Dermira in a research report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Five equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $43.80.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with our FREE daily email newsletter.